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Disclaimer:Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviders
to help them provide quality medical genetic services. Adherence to this guideline does not necessarily assure a successful medical
outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and
tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the
geneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatient
or specimen. It may be prudent, however, to document in the patient’s record the rationale for any significant deviation from this
guideline.
The familial nature of genetic conditions often requires the
testingofparentsandotherfamilymembersinordertodetermine
the relationship of a genetic change to a clinical phenotype or to
determine potential reproductive risks. When required as part of
prenatal and preconceptional genetic testing services, time con-
straints and the costs and risks of alternatives to testing parents
require that payers have established policies for how both mater-
nal and paternal tests that inform fetal testing choices or the in-
terpretation of fetal testing results will be covered.
INTRODUCTION
Genetictesting,inthecontextofaplannedorongoingpreg-
nancy, frequently poses special challenges to health care pro-
viders. Barriers to such testing may include: time constraints,
labor intensive laboratory procedures, the need to test more
than one family member, and/or inability of uninsured bio-
logic fathers to be tested, despite the fact that such testing is
being done for fetal diagnosis. As more and more genetic tests
are becoming standard of care for women who are, or may
become pregnant, we need to consider how best to provide
appropriate and efficient care for these patients.
ISSUES
● Problemsareoftenencounteredinthetestingofafetusor
pregnancy for genetic conditions when the mother is
identified to be a carrier of a genetic condition, and the
biologic father has neither insurance coverage nor the re-
sources to pay for carrier testing.
● If the father is unable to be screened, pregnant women
and their fetuses may undergo unnecessary invasive pro-
cedures, such as CVS or amniocentesis, that are also con-
siderably more expensive than carrier testing, in order to
determine if the fetus is affected.
● Carrier testing of prospective parents should be under-
taken in the safest and most cost effective way.
● Pregnancy itself imposes time limits for carrier testing
which also must be taken into consideration.
CONDITIONS TO BE TESTED FOR
Some common conditions (there are many not listed here)
● Carrier status for genetic conditions that are found fre-
quently in specific populations
● Hemoglobinopathies(sicklecelltrait,Ctrait,thalassemia
trait, hemoglobin E)
● Cystic fibrosis
● Tay-Sachs disease
● Canavan disease
Special circumstances
● Cytogenetic studies in the context of a suggestive family
history (i.e., recurrent pregnancy loss, a fetal cytogenetic
abnormality such as a chromosomal translocation, indi-
vidual with a known chromosomal rearrangement, indi-
vidual with multiple anomalies  mental retardation).
(Depending on the specific family history, cytogenetic
testing of only the male partner may be the appropriate
screening test.)
● Previous child or other family history of an individual
withaspecificgeneticdisorderthatisamenabletoprena-
tal diagnosis. (For some less common disorders in this
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134 Genetics IN Medicinecategory, preconception screening may be required in
order to permit adequate time for follow-up testing or
complex laboratory investigations, and to allow for the
more cost effective sequential, rather than simultaneous
testing.)
DISCUSSION
As more carrier screening tests are offered to women in the
context of a pregnancy at-risk for a genetic disorder, a mecha-
nismmustbeinplacetoprovidetimelyandaccuratediagnosis
for the lowest cost and with the fewest risks to the pregnant
woman and her developing fetus. Enabling biologic fathers to
be tested in order to adequately assess risk for an ongoing or
planned pregnancy is the first step toward attaining this goal.
Since fetal testing may be covered by the maternal insurance
plan, it is reasonable to expect that paternal testing for fetal
diagnosis would be reimbursed by the same insurer. From a
patient care perspective, the best time to perform carrier
screeningispriortoarecognizedpregnancy,asitallowscouple
to consider other reproductive options such as preimplanta-
tiongeneticdiagnosis,useofdonorgametes,oradoption.Yet,
many patients are not covered for such testing until a preg-
nancy is underway. Whereas some laboratories perform con-
current testing on expectant couples for fetal conditions (i.e.,
uniparental disomy) and are able to bill the insurer on a single
invoiceandgenerateasinglelaboratoryreport,thevastmajor-
ity of fetal diagnoses involving samples from multiple individ-
uals result in multiple invoices and multiple reports. Sequen-
tial testing of potential carrier couples may be even more
problematicinthisregard,butcertainlytheseobstaclesarenot
insurmountable.Giventheadvancesingenetichealthcareand
availability of preconceptional and prenatal carrier tests, the
time is at hand for health insurance carriers to come together
with clinical and laboratory health care providers to ensure
equitable coverage for fetal testing that optimizes care for pa-
tients across the US.
RECOMMENDATIONS
In light of the above, optimal care for a couple potentially
at-riskforadiagnosablegeneticdisorderintheirfetusrequires
that:
● Women be offered appropriate screening for carrier sta-
tus prior to conception. If this is not possible, then the
expectant mother should be screened as early as possible
in the prenatal period.
● Ifawomanisfoundtobeacarrierofanautosomalreces-
sive disorder, then the biologic father should be offered
carrier testing to assess the risk to their offspring.
● When a woman is tested at a more advanced gestational
age (i.e., after 14 weeks), she and the biologic father
shouldbetestedconcurrentlyratherthansequentiallybe-
cause of time constraints.
● Based on a significant paternal family history, testing of
the biologic father alone or initially may be recom-
mended.
● Whentestingofthebiologicfatherisindicated,suchtest-
ing should be covered as part of global obstetrical care.
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